Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial

Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data

(2021) Sean Wharton et al.   INTERNATIONAL JOURNAL OF OBESITY

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

(2021) Thomas A. Wadden et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

(2021) Melanie Davies et al.   LANCET

Once-Weekly Semaglutide in Adults with Overweight or Obesity

(2021) John P.H. Wilding et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity

(2021) Domenica Rubino et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Identification of type 2 diabetes loci in 433,540 East Asian individuals

(2020) Cassandra N. Spracklen et al.   NATURE

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

(2019) V. R Aroda et al.   DIABETES & METABOLISM

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2019) John B. Buse et al.   DIABETES CARE

Quantitative association between body mass index and the risk of cancer: A global Meta-analysis of prospective cohort studies

(2018) Xuexian Fang et al.   INTERNATIONAL JOURNAL OF CANCER

Progress and challenges in anti-obesity pharmacotherapy

(2018) Daniel H Bessesen et al.   Lancet Diabetes & Endocrinology

Obesity

(2017) Pedro González-Muniesa et al.   Nature Reviews Disease Primers

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials

(2016) Karolin Bettge et al.   DIABETES OBESITY & METABOLISM

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY

(2016) W. Timothy Garvey et al.   Endocrine Practice

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

(2015) Xavier Pi-Sunyer et al.   NEW ENGLAND JOURNAL OF MEDICINE

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Three percent weight reduction is the minimum requirement to improve health hazards in obese and overweight people in Japan

(2013) Akiko Muramoto et al.   Obesity Research & Clinical Practice

Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: the International Study of Prediction of Intra-Abdominal Adiposity and Its Relationship With Cardiometabolic Risk/Intra-Abdominal Adiposity

(2012) Julie-Anne Nazare et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Association between Body-Mass Index and Risk of Death in More Than 1 Million Asians

(2011) Wei Zheng et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Persistence of Hormonal Adaptations to Weight Loss

(2011) Priya Sumithran et al.   NEW ENGLAND JOURNAL OF MEDICINE